Continuous Hyperthermia Cancer Treatment Market: Rising Cancer Prevalence Is Attributed as the Chief Growth Driver for this Market

Award-winning consulting firm Fact.MR has recently published an extensive report on the global market for hyperthermia cancer treatment for the forecast period of 2021-2031. According to the study, the market is anticipated to accrue impressive gains, expanding at a CAGR of around 6% to surpass a valuation of US$ 250 million by 2031. Rising cancer prevalence is attributed as the chief growth driver for this market.

The International Agency for Research on Cancer (IARC) estimates that, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, respectively. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. Also, according to the World Health Organization, breast cancer is the most commonly occurring cancer in women and the second-most common cancer overall. Over 2 million new cases of breast cancer were diagnosed across the world in 2018. Hence, the scope for incorporating sophisticated treatments is increasing, paving way for enhanced adoption of hyperthermia cancer treatment.

For more insights into the Market, Request a Sample of this Report

Furthermore, various governmental initiatives to fund extensive cancer research programs are proving to be a boon for market growth. For instance, in April 2016, the U.S. Government allotted US$ 5.2 billion to the National Cancer Institute (NCI) for cancer research and training. This has enabled the U.S. healthcare system to deploy a host of advanced cancer treatment and diagnosis solutions.

Key Take aways from Market Study

  • Microwave hyperthermia cancer treatment devices to account for over 40% revenue share through 2031
  • By application, treatment for breast cancer to remain key revenue generator
  • Prospects for deep tissue ®ional perfusion appear highly promising, expected to post significant gains
  • By enduser, hospitals to yield over two-fifth of the global revenue share through 2031
  • High cancer incidence and prevalence rates to stimulate demand across the U.S.
  • The U.K. to stimulate high demand amid growing preference for minimally invasive cancer treatment
  • Rapid advancements in medical technology to bolster uptake across France and Germany

“Rising demand for improving clinical outcomes and inflicting minimal patient discomfort is prompting healthcare providers to deploy a broad range of advanced surgical and therapeutic options, including high intensity focused ultrasound (HIFU), widening the growth prospects of market players,” says a Fact.MR analyst.

Get Customization on this Research Report for specific research solutions

Key Market Segments Covered

  • Device
    • Infrared Devices for Hyperthermia Cancer Treatment
    • Magnetic Hyperthermia Devices
    • Ultrasound Hyperthermia Devices
    • Microwave Devicesfor Hyperthermia Cancer Treatment
    • Others
  • Treatment Method
    • Loco-regional Method
    • External & Interstitial
    • Intraluminal or Endocavitary Methods
    • Continuous Hyperthermic Peritoneal Perfusion (CHPP)
    • Deep Tissue & Regional Perfusion
    • Whole Body
  • Application
    • Breast Cancer
    • Liver Cancer
    • Soft Tissue Sarcoma
    • Head & Neck Tumors
    • Prostate Cancer
    • Others
  • End User
    • for Hyperthermia Cancer Treatment at Hospitals & Specialty Clinics
    • for Hyperthermia Cancer Treatment at Ambulatory Surgical Centers
    • Others
  • Region
    • North America
      • US
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia & New Zealand
      • Rest of APAC
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC
      • South Africa
      • Rest of MEA

Full Access of this Report Is Available at

Competitive Landscape

Fact.MR’s has profiled the following hyperthermia cancer treatment solution providers in its research report: PYREXAR Medical, Celsius42 GmbH, Hydrosun GmbH, Oncotherm Kft., Andromedic S.r.l., Yamamoto Vinita Co. Ltd, Chongqing Haifu Medical Technology Co. Ltd., innoMedicus Ltd., Gamida-Cell Ltd., and RanD. Some key expansion strategies deployed by the afore mentioned players include strengthening distribution networks and introducing new approaches to treat and diagnose potential cancers.

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the hyperthermia cancer treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of device (infrared devices, ultrasound devices, microwave devices, and others), treatment method (loco-regional and whole body), application (breast cancer, liver cancer, soft tissue sarcoma, head & neck tumors, prostate cancer, and others) and enduser (hospitals & specialty clinics, ambulatory surgical centers, and others) across five major regions of the world (North America, Europe, Latin America, AsiaPacific, and the Middle East & Africa).

For More Insights

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates